Usefulness of metabolic syndrome score in the prediction of angiographic coronary artery disease severity according to the presence of diabetes mellitus: Relation with inflammatory markers and adipokines

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Kim, Jong Youn ^a   Choi, Eui Young ^a   Mun, Hee Sun ^a   Min, Pil Ki ^a   Yoon, Young Won ^a   Lee, Byoung K ^a   Hong, Bum Kee ^a   Rim, Se Joong ^a   Kwon, Hyuck M ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adipokines; Coronary artery disease; Diabetes mellitus; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 6; RESISTIN;

ADULT; AGE; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; EDUCATION PROGRAM; FEMALE; GENSINI SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTION; SENSITIVITY ANALYSIS; THORAX PAIN;

ADIPOKINES; ADIPONECTIN; AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RESISTIN; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84884758042     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-140     Document Type: Article

References (31)

1. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28(7):1769-1778. 10.2337/diacare.28.7.1769, 15983333.
2. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. American J Med 2006, 119(10):812-819.
3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49(4):403-414. 10.1016/j.jacc.2006.09.032, 17258085.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689. 10.2337/diacare.24.4.683, 11315831.
5. Solymoss BC, Bourassa MG, Lesperance J, Levesque S, Marcil M, Varga S, Campeau L. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis 2003, 14(3):207-212.
6. Espinola-Klein C, Gori T, Blankenberg S, Munzel T. Inflammatory markers and cardiovascular risk in the metabolic syndrome. Front Biosci 2011, 16:1663-1674.
7. Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 2012, 10(7):933-939. 10.1586/erc.12.74, 22908926.
8. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr 2008, 32(6):638-644. 10.1177/0148607108325251, 3088110, 18974244.
9. Iribarren C. The metabolic syndrome is no better than its components. Minerva Cardioangiol 2007, 55(4):487-489.
10. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso M, Kuusisto J. The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns. Eur Heart J 2007, 28(7):857-864. 10.1093/eurheartj/ehl524, 17303589.
11. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, Levesque S, Varga S. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American J Cardiol 2004, 93(2):159-164.
12. Kim JY, Mun HS, Lee BK, Yoon SB, Choi EY, Min PK, Yoon YW, Hong BK, Rim SJ, Kwon HM. Impact of metabolic syndrome and its individual components on the presence and severity of angiographic coronary artery disease. Yonsei Med J 2010, 51(5):676-682. 10.3349/ymj.2010.51.5.676, 2908873, 20635441.
13. Yoon SE, Ahn SG, Kim JY, Park JS, Shin JH, Tahk SJ, Lee SK, Kim TJ, Han N. Differential relationship between metabolic syndrome score and severity of coronary atherosclerosis as assessed by angiography in a non-diabetic and diabetic Korean population. J Korean Med Sci 2011, 26(7):900-905. 10.3346/jkms.2011.26.7.900, 3124720, 21738343.
14. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. 10.1007/BF00280883, 3899825.
16. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. American J Cardiol 1983, 51(3):606.
17. Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Matsui K, Sakamoto T, Yoshimura M, Kimura K, Umemura S, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol 2006, 48(6):1155-1162. 10.1016/j.jacc.2006.05.054, 16978998.
18. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. New England J Med 2005, 353(1):46-57.
19. Sukhija R, Fahdi I, Garza L, Fink L, Scott M, Aude W, Pacheco R, Bursac Z, Grant A, Mehta JL. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. American J Cardiol 2007, 99(7):879-884.
20. Baldasseroni S, Antenore A, Di Serio C, Orso F, Lonetto G, Bartoli N, Foschini A, Marella A, Pratesi A, Scarantino S, et al. Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetology 2012, 11:151.
21. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
22. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56(14):1113-1132. 10.1016/j.jacc.2010.05.034, 20863953.
23. Mouquet F, Cuilleret F, Susen S, Sautiere K, Marboeuf P, Ennezat PV, McFadden E, Pigny P, Richard F, Hennache B, et al. Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J 2009, 30(7):840-849. 2663725, 19164335.
24. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005, 366(9497):1640-1649. 10.1016/S0140-6736(05)67663-5, 16271645.
25. Hutley L, Prins JB. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 2005, 330(6):280-289. 10.1097/00000441-200512000-00005, 16355012.
26. Kim HM, Kim KJ, Lee HJ, Yu HT, Moon JH, Kang ES, Cha BS, Lee HC, Lee BW, Kim YJ. Epicardial adipose tissue thickness is an indicator for coronary artery stenosis in asymptomatic type 2 diabetic patients: its assessment by cardiac magnetic resonance. Cardiovasc Diabetology 2012, 11:83.
27. Siitonen N, Pulkkinen L, Lindstrom J, Kolehmainen M, Schwab U, Eriksson JG, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M. Association of ADIPOR2 gene variants with cardiovascular disease and type 2 diabetes risk in individuals with impaired glucose tolerance: the Finnish Diabetes Prevention Study. Cardiovasc Diabetology 2011, 10:83.
28. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28(9):2289-2304. 10.2337/diacare.28.9.2289, 16123508.
29. Liang KW, Lee WJ, Lee WL, Chen YT, Ting CT, Sheu WH. Diabetes exacerbates angiographic coronary lesion progression in subjects with metabolic syndrome independent of CRP levels. Clinica Chimica Acta; Int J Clin Chem 2008, 388(1-2):41-45.
30. Martin-Cordero L, Garcia JJ, Hinchado MD, Ortega E. The interleukin-6 and noradrenaline mediated inflammation-stress feedback mechanism is dysregulated in metabolic syndrome: effect of exercise. Cardiovasc Diabetology 2011, 10:42.
31. Antoniades C, Tousoulis D, Marinou K, Papageorgiou N, Bosinakou E, Tsioufis C, Stefanadi E, Latsios G, Tentolouris C, Siasos G, et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol 2007, 30(6):295-300. 10.1002/clc.20101, 17551966.